Follistantin 1mg 10 Vials–Min order 200 vials

Description

Follistatin Myostatin Antagonist for Muscle Hypertrophy Research

Mechanism Overview

The biochemical activity of Follistatin 344/315 is defined by its role as a high-affinity “ligand trap.” Initially, the protein binds directly to myostatin (GDF-8) and activin A with nearly irreversible affinity, preventing these ligands from interacting with the Activin Receptor Type IIB (ActRIIB) on muscle cell membranes. This defines the first semantic triple: [Follistatin neutralizes GDF-8]. Following this, this neutralization effectively halts the SMAD2/3 signaling pathway, which normally functions to suppress muscle protein synthesis. This establishes the second triple: [Follistatin inhibition suppresses SMAD signaling]. Thirdly, the reduction in inhibitory signaling triggers the activation and proliferation of dormant satellite cells, facilitating both hypertrophy (cell size) and hyperplasia (cell number). This forms the third triple: [Myostatin blockade drives satellite cell proliferation]. Quantitatively, FS-315 is unique because it contains a C-terminal acidic tail that reduces its affinity for heparin-sulfate proteoglycans, allowing it to remain in the bloodstream longer than other isoforms.

Overview

Follistatin (FST) is a single-chain glycosylated protein that acts as a potent regulator of the Transforming Growth Factor-beta (TGF-??) superfamily. In research models, the 344-amino acid precursor (FS-344) undergoes post-translational modification to become the serum-circulating 315-isoform (FS-315). Unlike the membrane-bound FS-288 variant, the 344/315 lineage is specifically characterized by its ability to circulate systemically, making it the primary tool for investigating whole-body musculoskeletal remodeling and the inhibition of negative growth regulators. [Follistatin binds Myostatin].

Molecular Data

• CAS Number: 129954-34-3 (Reference)
• Molecular Weight: ~35?C45 kDa (Glycosylated monomer)
• Sequence: 344 Amino Acid Precursor / 315 Amino Acid Circulating Form
• Purity: >99.0% via HPLC-UV and Mass Spectrometry
• Appearance: Sterile filtered white lyophilizate

Research Observations

• Rapid Accumulation of Lean Mass: Users report significant increases in skeletal muscle density and volume within 2 to 4 weeks of administration.
• Myogenic Stem Cell Activation: Published research indicates enhanced recovery from micro-trauma through the recruitment of new myonuclei.
• Modulation of Adipose Tissue: According to research documentation, research models show a secondary reduction in body fat as lean tissue metabolic demand increases.
• Connective Tissue Support: Aggregated data shows improved tendon and ligament integrity, likely due to the modulation of TGF-??-mediated fibrosis.
• Follicle-Stimulating Hormone (FSH) Regulation: Research models have observed a dose-dependent suppression of FSH, which is a hallmark of follistatin’s endocrine signaling.

Key Points:
Follistatin 344/315 represents a premier research tool for investigating the profound effects of systemic myostatin inhibition on muscular hypertrophy and cellular regeneration.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.